The in vitro binding properties of non-peptide AT1 receptor antagonists

Journal of Clinical and Basic Cardiology

Volumn 5, Issue 1, 2002, Pages 75-82

  Vanderheyden, P M L ^a   Verheijen, I ^a   Fierens, F L P ^a   Vauquelin, G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Angiotensin II; AT1 receptor; CHO cells; Insurmountable; Surmountable

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

BINDING AFFINITY; BINDING SITE; BLOOD PRESSURE MEASUREMENT; DISSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; TREATMENT PLANNING;

EID: 0036240351     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. The renin-angiotensin system
2. Angiotensin antagonists
3. Angiotensin II receptors and functional correlates
4. Angiotensin II receptor binding inhibitors
5. Nonpeptide angiotensin II receptor antagonists
6. Angiotensin II receptor antagonist in hypertension
7. Direct selective blockade of the vascular angiotensin II receptor in therapy for hypertension and severe congestive heart failure
8. A new class of anti hypertensive therapy: Angiotensin II receptor antagonists
9. Newly emerging pharmacologic differences in angiotensin II receptor blockers
10. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist
11. Nonpeptide angiotensin receptor antagonists. VII Characterization of functional antagonism displayed by Dup 753, an orally active antihypertensive agent
12. Pharmacological properties of angiotensin II receptor antagonists
13. 1 receptor antagonist
14. 1-receptor subtype
15. 1 subtype angiotensin II receptor antagonist
16. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new neuropeptide AII antagonist
17. 1-receptor antagonist in rabbit tissues
18. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
19. Pharmacological profile of GR 117289 in vitro: A novel, potent and specific non-peptide angiotensin AT1 receptor antagonist
20. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629
21. 1 receptor antagonist
22. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174
23. 1 receptor antagonist, UR-7280
24. 1 antagonism
25. 1 receptors
26. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese Hamster Ovary cells expressing human angiotensin II type I receptors
27. Desensitization, two-state receptors and pharmacological parameters
28. Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model
29. The serotonin-S2 receptor: A receptor, transducer coupling model to explain insourmountable antagonist effects
30. 1 receptor-transfected Chinese hamster ovary cells
31. 3H]-irbesartan to human recombinant angiotensin type 1 receptors
32. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type I receptors
33. Theory for ligand rebinding at cell membrane surfaces
34. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor
35. 1 receptor antagonists: The role of tight antagonist binding
36. 1 receptor antagonists
37. The two-state model of receptor activation
38. A two-state receptor model for the interaction between angiotensin II type I receptors and non-peptide antagonists
39. 2 receptors: Evidence for selective sorting of receptor and ligand
40. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and synoptic action
41. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor
42. 3H]-candesartan is independent of receptor internalization
43. 1 angiotensin receptors
44. 3H-Nalaxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells; evidence for G-protein dependent antagonist binding
45. A review of mutagenesis studies on angiotensin II type I receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism
46. Lys199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists
47. Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists
48. 1) receptor by a highly potent phenoxyroline octanoaminde
49. 1 receptors
50. 1-receptor blockers in isolated vessels of different origin
51. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
52. A comparison of the efficacy, duration of action of candesartan cilexetil, losartan as assessed by clinic, ambulatory, blood pressure after a missed dose, in truly hypertensive patients
53. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
54. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action
55. Short-term and sustained renal affects of angiotensin II blockade in healthy subjects
56. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects